FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310107589> ?p ?o ?g. }

• W4310107589 endingPage "10653" @default.
• W4310107589 startingPage "10652" @default.
• W4310107589 abstract "Background In China, it is estimated that there are 15,000-30,000 patients with β Thalassemia Major (β-TM). Our recent Cross-sectional survey of β-TM patients’ conditions in China found that only 7% of patients with β-TM expect to live beyond age 18, and only a fraction of patients have received allogeneic hematopoietic stem cell transplantation. Higher level of fetal hemoglobin (HbF) by downregulation of BCL11A during erythroid differentiation has been reported to ameliorate the clinical severity of the patients with β-TM. Disruption of GATAA motif in DHS h+58 region of BCL11A erythroid enhancer (BEE) by gene editing in CD34+ cells has been shown to significantly induce the production of HbF in patients. An adjacent motif, i.e., the CTG motif within TAL1-GATA1 binding site could potentially also be such a gene-editing target due to naturally occurring SNPs associated with elevated HbF levels (eg rs1427407). ET-01 is an investigational cell therapy product comprised of autologous CD34+ cells that have undergone CRISPR/Cas9-mediated ex vivo editing targeting this motif (Fig 1). Methods The EDI-001 trial (NCT04390971) aimed to evaluate the safety and efficacy of ET-01 in patients with transfusion dependent thalassemia (TDT). Patients (aged 6 to 35 years) with TDT whose total hemoglobin level fell within the range of 4.5g/dL and 7g/dL were eligible. One patient was enrolled and CD34+ cells were collected from the patient by apheresis following mobilization with lenograstim and plerixafor. ET-01 was manufactured by editing at BEE with Cas9 mRNA and a specific single-guide RNA via electroporation. The ET-01 product was infused following myeloablative conditioning on date 18 Nov 2020 (patient age at 12). Afterwards, the patient was followed up per schedule defined in the Protocol, monitoring safety and efficacy endpoints. Results cGMP manufacturing process at clinical scale was developed for ET-01. High editing rate was achieved with stemness well maintained (Fig 2A). Indels pattern analysis showed that in ET-01 four indel types were most prevalent (Fig 2B). Moreover, the percentage of HbF+ cells were significantly increased compared with the unedited CD34+ cells in erythroid differentiation assay (Fig 2C). IND-enabling studies showed that no tumorigenicity nor other toxicities associated with ET-01 were observed in over 400 mice at up to 40 weeks of observation. One patient (β0/β+) was enrolled, for which ET-01 was manufactured under cGMP process and infused at a dose of 23.19 X 10^6 CD34+ cells/kg. Successful hematopoietic reconstitution was observed, in which neutrophil engraftment occurred on day 24 and platelet engraftment on day 37 post ET-01 infusion. The patient experienced a significant increase of HbF production and total Hb, in which the levels of HbF increased from 3.35 g/L at baseline to 89.87 g/L, and the total hemoglobin level reached 110 g/L at month 18, respectively (Fig 3). The patient received her last pRBCs transfusion on day 87 after ET-01 infusion, and achieved transfusion-free for over 15 months. Moreover, we observed that the prevalence of indels changed during the initial few weeks and remained stable in both peripheral blood and bone marrow (Fig 4A). NGS analysis of 42 potential off-target sites, discovered by in silico prediction and DiGenome-seq, showed editing efficiencies below 1%, and no significant change was observed in any of the 42 sites throughout visits (Fig 4B). The patient experienced 62 cases of adverse events, most of which were Grade 1 or 2 in severity. Of these, only one Grade 1 AE was attributed to the ET-01 drug product, caused by the ET-01 preparation component DMSO during infusion, and was gradually relieved by adjusting the infusion rate. Two Grade 3 serious adverse events (SAE) unrelated to ET-01 were reported: enterocolitis and febrile neutropenia, caused by inappropriate diet after apheresis and busulfan conditioning, respectively. Conclusions These data demonstrated that a single-dose of ET-01 composed of autologous CRISPR/Cas9 mediated CD34+ cells led to the timely hematopoietic engraftment, significant and durable increases in HbF production and total Hb, and transfusion-independent for 15 months at the time of data cut-off. Safety profile of ET-01 is consistent with that of autologous HSC transplant including busulfan myeloablative conditioning. These preliminary results support further experimental testing of ET-01 to treat patients with β-TM. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310107589 created "2022-11-30" @default.
• W4310107589 creator A5000987583 @default.
• W4310107589 creator A5005105786 @default.
• W4310107589 creator A5010607811 @default.
• W4310107589 creator A5011164870 @default.
• W4310107589 creator A5013582226 @default.
• W4310107589 creator A5017263150 @default.
• W4310107589 creator A5025685483 @default.
• W4310107589 creator A5030241946 @default.
• W4310107589 creator A5032873197 @default.
• W4310107589 creator A5036054382 @default.
• W4310107589 creator A5037951357 @default.
• W4310107589 creator A5040793026 @default.
• W4310107589 creator A5042738110 @default.
• W4310107589 creator A5043910391 @default.
• W4310107589 creator A5044999911 @default.
• W4310107589 creator A5046454314 @default.
• W4310107589 creator A5047118986 @default.
• W4310107589 creator A5048351662 @default.
• W4310107589 creator A5054352845 @default.
• W4310107589 creator A5054739067 @default.
• W4310107589 creator A5059062052 @default.
• W4310107589 creator A5059368182 @default.
• W4310107589 creator A5059827958 @default.
• W4310107589 creator A5059906168 @default.
• W4310107589 creator A5060867127 @default.
• W4310107589 creator A5061220897 @default.
• W4310107589 creator A5061336466 @default.
• W4310107589 creator A5061738324 @default.
• W4310107589 creator A5064354572 @default.
• W4310107589 creator A5069771802 @default.
• W4310107589 creator A5073332002 @default.
• W4310107589 creator A5076213855 @default.
• W4310107589 creator A5085930167 @default.
• W4310107589 creator A5088525790 @default.
• W4310107589 creator A5089393558 @default.
• W4310107589 date "2022-11-15" @default.
• W4310107589 modified "2023-10-08" @default.
• W4310107589 title "Preliminary Safety and Efficacy Results of EDI001: An Investigator Initiated Trial on CRISPR/Cas9-Modified Autologous CD34+ Hematopoietic Stem and Progenitor Cells for Patients with Transfusion Dependent β-Thalassemia" @default.
• W4310107589 doi "https://doi.org/10.1182/blood-2022-166365" @default.
• W4310107589 hasPublicationYear "2022" @default.
• W4310107589 type Work @default.
• W4310107589 citedByCount "1" @default.
• W4310107589 countsByYear W43101075892023 @default.
• W4310107589 crossrefType "journal-article" @default.
• W4310107589 hasAuthorship W4310107589A5000987583 @default.
• W4310107589 hasAuthorship W4310107589A5005105786 @default.
• W4310107589 hasAuthorship W4310107589A5010607811 @default.
• W4310107589 hasAuthorship W4310107589A5011164870 @default.
• W4310107589 hasAuthorship W4310107589A5013582226 @default.
• W4310107589 hasAuthorship W4310107589A5017263150 @default.
• W4310107589 hasAuthorship W4310107589A5025685483 @default.
• W4310107589 hasAuthorship W4310107589A5030241946 @default.
• W4310107589 hasAuthorship W4310107589A5032873197 @default.
• W4310107589 hasAuthorship W4310107589A5036054382 @default.
• W4310107589 hasAuthorship W4310107589A5037951357 @default.
• W4310107589 hasAuthorship W4310107589A5040793026 @default.
• W4310107589 hasAuthorship W4310107589A5042738110 @default.
• W4310107589 hasAuthorship W4310107589A5043910391 @default.
• W4310107589 hasAuthorship W4310107589A5044999911 @default.
• W4310107589 hasAuthorship W4310107589A5046454314 @default.
• W4310107589 hasAuthorship W4310107589A5047118986 @default.
• W4310107589 hasAuthorship W4310107589A5048351662 @default.
• W4310107589 hasAuthorship W4310107589A5054352845 @default.
• W4310107589 hasAuthorship W4310107589A5054739067 @default.
• W4310107589 hasAuthorship W4310107589A5059062052 @default.
• W4310107589 hasAuthorship W4310107589A5059368182 @default.
• W4310107589 hasAuthorship W4310107589A5059827958 @default.
• W4310107589 hasAuthorship W4310107589A5059906168 @default.
• W4310107589 hasAuthorship W4310107589A5060867127 @default.
• W4310107589 hasAuthorship W4310107589A5061220897 @default.
• W4310107589 hasAuthorship W4310107589A5061336466 @default.
• W4310107589 hasAuthorship W4310107589A5061738324 @default.
• W4310107589 hasAuthorship W4310107589A5064354572 @default.
• W4310107589 hasAuthorship W4310107589A5069771802 @default.
• W4310107589 hasAuthorship W4310107589A5073332002 @default.
• W4310107589 hasAuthorship W4310107589A5076213855 @default.
• W4310107589 hasAuthorship W4310107589A5085930167 @default.
• W4310107589 hasAuthorship W4310107589A5088525790 @default.
• W4310107589 hasAuthorship W4310107589A5089393558 @default.
• W4310107589 hasBestOaLocation W43101075891 @default.
• W4310107589 hasConcept C10205521 @default.
• W4310107589 hasConcept C109159458 @default.
• W4310107589 hasConcept C126322002 @default.
• W4310107589 hasConcept C201750760 @default.
• W4310107589 hasConcept C2777799968 @default.
• W4310107589 hasConcept C28328180 @default.
• W4310107589 hasConcept C54355233 @default.
• W4310107589 hasConcept C71924100 @default.
• W4310107589 hasConcept C86803240 @default.
• W4310107589 hasConceptScore W4310107589C10205521 @default.
• W4310107589 hasConceptScore W4310107589C109159458 @default.
• W4310107589 hasConceptScore W4310107589C126322002 @default.
• W4310107589 hasConceptScore W4310107589C201750760 @default.
• W4310107589 hasConceptScore W4310107589C2777799968 @default.
• W4310107589 hasConceptScore W4310107589C28328180 @default.
• W4310107589 hasConceptScore W4310107589C54355233 @default.

• next